Out of 61 people with HIV and fatty liver in the study, 39 were on INSTI drugs, and most of those (41%) were taking dolutegravir.

Scientific Claim

Among 61 participants with HIV-associated non-alcoholic fatty liver disease (NAFLD) in the study, 39 (64%) were taking integrase inhibitor (INSTI)-containing regimens, with dolutegravir being the most common INSTI (41% of the INSTI subgroup).

Original Statement

“Amongst participants, 39 (64%) were on INSTI containing regimens, the most common of which was dolutegravir (41%).”

From study:1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

definitive

Can make definitive causal claims

Assessment Explanation

This is a straightforward description of the study population, which the study directly reports. No causal language is needed, so the claim is appropriately stated.

Evidence from Studies

Supporting (1)

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Randomized Controlled Trial

Human

Contradicting (0)

No contradicting evidence found

Source Study

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Score: 63

DOI: 10.1093/ofid/ofad500.1334

Similar Assertions

Out of 61 people with HIV and fatty liver disease in the study, 39 were taking integrase inhibitors, and most of those (41% of all participants) were on dolutegravir.

95%

In the study, most people with HIV and fatty liver disease on INSTI drugs were taking dolutegravir, which made up 41% of those on INSTIs.

91%

For people with HIV and fatty liver on INSTI drugs, taking a placebo for a year leads to a 10.8% increase in belly fat.

82%

Before starting treatment, people with HIV and fatty liver disease who were taking integrase inhibitors had similar body measurements as those not taking them.

81%

Researchers looked at data from a previous study where 61 people with HIV and fatty liver disease were given either tesamorelin or a placebo, then focused on those taking integrase inhibitor drugs.

81%